Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTE85L1Q)

• DOT Name: Alternative prion protein (PRNP)
• Synonyms: AltPrP
• Gene Name: PRNP
• Related Disease:
  Gerstmann-Straussler-Scheinker syndrome
  Huntington disease-like 1
  Inherited Creutzfeldt-Jakob disease
  Familial Alzheimer-like prion disease
  Fatal familial insomnia
  PrP systemic amyloidosis
• UniProt ID: APRIO_HUMAN
• Sequence:
  MEHWGQPIPGAGQPWRQPLPTSGRWWLGAASWWWLGAASWWWLGAAPWWWLGTASWWWLG
  SRRWHPQSVEQAE
• Tissue Specificity: Detected in brain homogenate, primary neurons, and peripheral blood mononuclear cells (at protein level).

Molecular Interaction Atlas (MIA) of This DOT

6 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Gerstmann-Straussler-Scheinker syndrome	DISIO6KC	Definitive	Autosomal dominant	[1]
Huntington disease-like 1	DIS82Q7U	Strong	Autosomal dominant	[2]
Inherited Creutzfeldt-Jakob disease	DIS3TXG8	Strong	Autosomal dominant	[2]
Familial Alzheimer-like prion disease	DISIRPQ9	Supportive	Autosomal dominant	[3]
Fatal familial insomnia	DIS1FL1J	Supportive	Autosomal dominant	[4]
PrP systemic amyloidosis	DISI16D9	Supportive	Autosomal dominant	[5]

This DOT Affected the Drug Response of 4 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Doxorubicin	DMVP5YE	Approved	Alternative prion protein (PRNP) decreases the response to substance of Doxorubicin.	[31]
Cisplatin	DMRHGI9	Approved	Alternative prion protein (PRNP) decreases the response to substance of Cisplatin.	[31]
Fluorouracil	DMUM7HZ	Approved	Alternative prion protein (PRNP) decreases the response to substance of Fluorouracil.	[31]
Etoposide	DMNH3PG	Approved	Alternative prion protein (PRNP) decreases the response to substance of Etoposide.	[31]

26 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate increases the expression of Alternative prion protein (PRNP).	[6]
Ciclosporin	DMAZJFX	Approved	Ciclosporin increases the expression of Alternative prion protein (PRNP).	[7]
Tretinoin	DM49DUI	Approved	Tretinoin decreases the expression of Alternative prion protein (PRNP).	[8]
Acetaminophen	DMUIE76	Approved	Acetaminophen increases the expression of Alternative prion protein (PRNP).	[9]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate increases the expression of Alternative prion protein (PRNP).	[10]
Estradiol	DMUNTE3	Approved	Estradiol increases the expression of Alternative prion protein (PRNP).	[11]
Hydrogen peroxide	DM1NG5W	Approved	Hydrogen peroxide increases the expression of Alternative prion protein (PRNP).	[12]
Calcitriol	DM8ZVJ7	Approved	Calcitriol increases the expression of Alternative prion protein (PRNP).	[13]
Carbamazepine	DMZOLBI	Approved	Carbamazepine affects the expression of Alternative prion protein (PRNP).	[14]
Methotrexate	DM2TEOL	Approved	Methotrexate decreases the expression of Alternative prion protein (PRNP).	[15]
Progesterone	DMUY35B	Approved	Progesterone increases the expression of Alternative prion protein (PRNP).	[16]
Panobinostat	DM58WKG	Approved	Panobinostat increases the expression of Alternative prion protein (PRNP).	[17]
Bortezomib	DMNO38U	Approved	Bortezomib increases the expression of Alternative prion protein (PRNP).	[18]
Cytarabine	DMZD5QR	Approved	Cytarabine decreases the expression of Alternative prion protein (PRNP).	[19]
Mitomycin	DMH0ZJE	Approved	Mitomycin increases the expression of Alternative prion protein (PRNP).	[20]
Pioglitazone	DMKJ485	Approved	Pioglitazone increases the expression of Alternative prion protein (PRNP).	[21]
Melatonin	DMKWFBT	Approved	Melatonin increases the expression of Alternative prion protein (PRNP).	[21]
Urethane	DM7NSI0	Phase 4	Urethane increases the expression of Alternative prion protein (PRNP).	[23]
SNDX-275	DMH7W9X	Phase 3	SNDX-275 increases the expression of Alternative prion protein (PRNP).	[17]
Tamibarotene	DM3G74J	Phase 3	Tamibarotene affects the expression of Alternative prion protein (PRNP).	[8]
Genistein	DM0JETC	Phase 2/3	Genistein increases the expression of Alternative prion protein (PRNP).	[24]
PMID28870136-Compound-52	DMFDERP	Patented	PMID28870136-Compound-52 decreases the expression of Alternative prion protein (PRNP).	[24]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A decreases the expression of Alternative prion protein (PRNP).	[26]
Trichostatin A	DM9C8NX	Investigative	Trichostatin A increases the expression of Alternative prion protein (PRNP).	[27]
Formaldehyde	DM7Q6M0	Investigative	Formaldehyde increases the expression of Alternative prion protein (PRNP).	[28]
chloropicrin	DMSGBQA	Investigative	chloropicrin decreases the expression of Alternative prion protein (PRNP).	[29]

2 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Tetracycline	DMZA017	Approved	Tetracycline affects the binding of Alternative prion protein (PRNP).	[22]
Trifluoroethanol	DMAWTUL	Investigative	Trifluoroethanol affects the folding of Alternative prion protein (PRNP).	[30]

1 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the methylation of Alternative prion protein (PRNP).	[25]

References

• [1] Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
• [2] The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
• [3] Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype. Ann Neurol. 2011 Apr;69(4):712-20. doi: 10.1002/ana.22264. Epub 2011 Mar 17.
• [4] Genetic Prion Disease. 2003 Mar 27 [updated 2021 Jan 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews(?) [Internet]. Seattle (WA): University of Washington, Seattle; 1993C2024.
• [5] A novel prion disease associated with diarrhea and autonomic neuropathy. N Engl J Med. 2013 Nov 14;369(20):1904-14. doi: 10.1056/NEJMoa1214747.
• [6] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [7] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [8] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [9] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [10] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [11] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [12] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [13] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [14] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [15] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [16] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [17] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [18] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [19] Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
• [20] Genomic and proteomic profiling of responses to toxic metals in human lung cells. Environ Health Perspect. 2003 May;111(6):825-35.
• [21] Co-Administration of Melatonin Effectively Enhances the Therapeutic Effects of Pioglitazone on Mesenchymal Stem Cells Undergoing Indoxyl Sulfate-Induced Senescence through Modulation of Cellular Prion Protein Expression. Int J Mol Sci. 2018 May 4;19(5):1367. doi: 10.3390/ijms19051367.
• [22] Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol. 2000 Jul 28;300(5):1309-22. doi: 10.1006/jmbi.2000.3840.
• [23] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [24] Caffeine overcomes genistein-induced G2/M cell cycle arrest in breast cancer cells. Nutr Cancer. 2008;60(3):382-8.
• [25] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [26] Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells. Toxicol Appl Pharmacol. 2010 Oct 15;248(2):111-21.
• [27] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [28] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [29] Transcriptomic analysis of human primary bronchial epithelial cells after chloropicrin treatment. Chem Res Toxicol. 2015 Oct 19;28(10):1926-35.
• [30] Membrane interactions and conformational preferences of human and avian prion N-terminal tandem repeats: the role of copper(II) ions, pH, and membrane mimicking environments. J Phys Chem B. 2010 Nov 4;114(43):13830-8. doi: 10.1021/jp1033036.
• [31] Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR. Int J Cancer. 2005 Jan 10;113(2):213-20. doi: 10.1002/ijc.20570.